Ramsay Health Care shares rebound 15% in June: Can they keep going?

Find out what the experts tip for the ASX healthcare shares next.

Ramsay Health Care Ltd (ASX: RHC) shares have climbed higher into the green on Thursday morning.

At the time of writing, the ASX healthcare shares are up around 1% and changing hands at $41.62 a piece.

Today's increase comes off the back of a 3.5% price hike yesterday.

The latest share price increase means Ramsay Health Care shares have now recovered around 15% from a dip in early June and are around 20% higher year to date. Over the past year, the shares have risen 17%.

Group of doctors celebrate by pumping fists in the air.

Image source: Getty Images

What happened to Ramsay Health Care shares?

Ramsay Health Care is one of the largest private healthcare providers in the world, with around 500 facilities across 11 countries. Its operations cover Australia, Europe, the UK, and Asia. 

The company faced several headwinds in 2025, including depressed earnings, market volatility, and ongoing cost pressures.

The ASX healthcare sector overall was under immense pressure throughout late 2025 and into early 2026, as macroeconomic pressures, rising inflation, higher cost of living, and regulatory uncertainty drove a sector-wide share price downturn.

Why are the ASX healthcare shares now rebounding?

There hasn't been any price-sensitive news out of Ramsay Health Care shares to explain the share price turnaround in June.

It's likely the result of an overall ASX healthcare sector recovery, as investors rotated back into heavily discounted healthcare names and sentiment improved following the company's latest earnings results.

The recovery has also been supported by a turnaround in the company's finances. Ramsay Health Care posted its first-half FY26 results in February, where it confirmed underlying EBIT had grown 7.3%, underlying NPAT was up 8.1%, and its Australian hospital revenue was 8.2% higher. The company's shares spiked by more than 10% on the day of the results.

The stronger half-year result seems to have helped investor sentiment shift from concerns about cost pressures and volatility towards a recovery story.

To me, it looks like investors are still snapping up the shares while they're trading for cheap.

Can Ramsay Health Care shares keep climbing higher? Here's what the experts think

Analysts and brokers are divided about the outlook for Ramsay Health Care shares over the next 12 months.

Market Index data shows brokers are split between a buy and a sell rating. The average $40.60 target price, however, implies a potential 3% downside at the time of writing.

On TradingView data, sentiment is also split. Out of 12 analysts, seven have a hold rating on the healthcare stock. Another four rate the shares as a buy or strong buy, and one has a strong sell stance.

The average $41.30 target price implies a downside of around 1% at the time of writing. But some expect the shares to jump 13% higher to $47.17, and others tip the stock to crash 20% back down to $32.90 a piece.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »